18f-fluorodeoxyglucose
1.Angiography and 18F-fluorodeoxyglucose-positron emission tomography (18FDG-PET) imaging were carried out in all patients.
2.18F-fluorodeoxyglucose PET is a very sensitive technology,yet it still has limitation such as low specificity.
3.Methods: Position emission tomography (PET) with [~(18)F]fluorodeoxyglucose was performed on 14 first-episode patients with major depressive disorders and 11 healthy volunteers.
4.Methods Sixteen T739 mice bearing the lung adenocarcinoma were randomly divided into two groups according to the different tracers. The biodistribution of mice for 18F-FLT and 18F-fluorodeoxyglucose(18F-FDG)was measured with well-gamma detector at 60 min after injection from tail veins. PET imaging was performed using two tracers.
5.Objective To explore the diagnostic value of 18 F-fluorodeoxyglucose (FDG) dual-head coincidence (DHC) imaging for detecting breast cancer and axillary lymph node metastases.
6.Objective To study the regional cerebral glucose utilization with 18F-fluorodeoxyglucose (FDG)/PET in advanced Parkinson’s disease (PD), and to investigate the imaging characteristics of advanced PD patients.
7.Methods 13 N-NH 3 and 18 F-fluorodeoxyglucose (FDG) PET imaging were performed in seven cases of astro cytomas including 3 anteoperative astrocytomas, 2 recurrent astrocytomas, 2 brai n injury o r necrosis after the operation and radiotherapy.
9.NEW YORK (Reuters Health) Dec 22 - Positron emission tomography (PET) following infusion of [18F] fluorodeoxyglucose (FDG) is an effective means of predicting response to neoadjuvant chemotherapy in patients with breast cancer, French researchers report in the December 1st issue of the Journal of Clinical Oncology.
